Loading...
Header Logo
Keywords
Last Name
Institution

HOMER A MACAPINLAC

TitleProfessor
InstitutionMD Anderson
DepartmentNuclear Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dai D, Chuang HH, Macapinlac HA, Li T, Pan T. Correlation of fluorine 18-labeled sodium fluoride uptake and arterial calcification on whole-body PET/CT in cancer patients. Nucl Med Commun. 2019 Jun; 40(6):604-610. PMID: 30688757.
      View in: PubMed
    2. Chen B, Macapinlac HA, Lu Y. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases. Clin Nucl Med. 2019 Apr; 44(4):337-338. PMID: 30688749.
      View in: PubMed
    3. Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. ESMO Open. 2019; 4(1):e000439. PMID: 30962954.
      View in: PubMed
    4. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 Feb 07. PMID: 30733229.
      View in: PubMed
    5. Lu Y, Sweiss NJ, Macapinlac HA. Prognostic Impact of FDG-PET/CT Images in Patients With Suspected Cardiac Sarcoidosis: Optimal Patient Preparation, Not Complex Unconventional Analytics, Is Key to Meaningful Data. JACC Cardiovasc Imaging. 2019 Jan; 12(1):217-219. PMID: 30621993.
      View in: PubMed
    6. Etchebehere E, Brito AE, Kairemo K, Rohren E, Araujo J, Macapinlac H. Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy? Radiol Bras. 2019 Jan-Feb; 52(1):33-40. PMID: 30804613.
      View in: PubMed
    7. Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 May 15; 24(10):2304-2311. PMID: 29476021.
      View in: PubMed
    8. Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Curr Radiopharm. 2018; 11(2):147-152. PMID: 29956640.
      View in: PubMed
    9. Lu Y, Chasen BA, Macapinlac HA. Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease. Clin Nucl Med. 2017 Dec; 42(12):980-982. PMID: 29076903.
      View in: PubMed
    10. Chism CB, Ravizzini GC, Macapinlac HA, Pan T. Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions. Nucl Med Commun. 2017 Jun; 38(6):529-536. PMID: 28383318.
      View in: PubMed
    11. Rohren EM, Macapinlac HA. Spectrum of Benign Bone Conditions on NaF-PET. Semin Nucl Med. 2017 07; 47(4):392-396. PMID: 28583278.
      View in: PubMed
    12. Kairemo K, Ravizzini GC, Macapinlac HA, Subbiah V. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma. Diagnostics (Basel). 2017 Apr 04; 7(2). PMID: 28375169.
      View in: PubMed
    13. Erwin WD, Jessop AC, Mar MV, Macapinlac HA, Mawlawi OR. Qualitative and quantitative comparison of gated blood pool single photon emission computed tomography using low-energy high-resolution and SMARTZOOM collimation. Nucl Med Commun. 2017 Jan; 38(1):35-43. PMID: 27775993.
      View in: PubMed
    14. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978. PMID: 27942837.
      View in: PubMed
    15. Etchebehere EC, Fox P, Milton D, Macapinlac H, Rohren E. Reply: Prediction vs. Prognostication and Guarantee-Time Bias: Steering Clear of the Pitfalls of Interpreting Observational Data. J Nucl Med. 2016 06; 57(6):991. PMID: 27081171.
      View in: PubMed
    16. Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73. PMID: 26828141.
      View in: PubMed
    17. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. Radiology. 2016 07; 280(1):220-9. PMID: 26854705.
      View in: PubMed
    18. Etchebehere EC, Hobbs BP, Milton DR, Malawi O, Patel S, Benjamin RS, Macapinlac HA. Assessing the role of ¹8F-FDG PET and ¹8F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2016 May; 43(5):860-70. PMID: 26631240.
      View in: PubMed
    19. Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016 Jan; 43(1):8-20. PMID: 26416392.
      View in: PubMed
    20. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52. PMID: 26321501.
      View in: PubMed
    21. Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12. PMID: 26135112.
      View in: PubMed
    22. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84. PMID: 26069307.
      View in: PubMed
    23. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6. PMID: 25157774.
      View in: PubMed
    24. Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL, Macapinlac HA, Chuang HH. Impact of ¹8F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014 Nov; 41(11):2066-73. PMID: 24990404.
      View in: PubMed
    25. Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH. The value of ¹8F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. 2014 Sep; 41(9):1756-66. PMID: 24699907.
      View in: PubMed
    26. Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol. 2014 Apr; 133(1):100-4. PMID: 24534359.
      View in: PubMed
    27. Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL, Macapinlac HA. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14. PMID: 24442598.
      View in: PubMed
    28. Bhosale P, Balachandran A, Vikram R, Viswanathan C, Macapinlac H, Rohren E, Prativadi R. What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies? Int J Mol Imaging. 2013; 2013:476786. PMID: 24455242.
      View in: PubMed
    29. Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013 Oct 20; 31(30):3823-30. PMID: 24043740.
      View in: PubMed
    30. Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT. Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. 2014 Jan-Feb; 21(1):3-8. PMID: 23911560.
      View in: PubMed
    31. Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7. PMID: 22810967.
      View in: PubMed
    32. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-42. PMID: 22831985.
      View in: PubMed
    33. Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA. Comparative study of the value of dual tracer PET/CT in evaluating breast cancer. Cancer Sci. 2012 Sep; 103(9):1701-7. PMID: 22632272.
      View in: PubMed
    34. Erasmus JJ, Macapinlac HA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med. 2012 Jul; 42(4):255-60. PMID: 22681674.
      View in: PubMed
    35. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8. PMID: 22586182.
      View in: PubMed
    36. Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology. 2012 Apr; 263(1):53-63. PMID: 22438441.
      View in: PubMed
    37. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887.
      View in: PubMed
    38. Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM. Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality. J Nucl Med Technol. 2011 Jun; 39(2):83-90. PMID: 21565950.
      View in: PubMed
    39. Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac H, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG. Evaluation of ¹8F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol. 2011 Oct; 18(10):2783-9. PMID: 21476107.
      View in: PubMed
    40. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33. PMID: 21456015.
      View in: PubMed
    41. Macapinlac HA, Czernin J, Larson SM. Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol. 2011 Feb; 13(1):1-2. PMID: 21082268.
      View in: PubMed
    42. Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE. Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies. Int J Mol Imaging. 2011; 2011:298102. PMID: 21490727.
      View in: PubMed
    43. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM. Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34. PMID: 21509770.
      View in: PubMed
    44. Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94. PMID: 20629031.
      View in: PubMed
    45. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010 Sep; 90(3):884-90; discussion 890-1. PMID: 20732513.
      View in: PubMed
    46. Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22. PMID: 20699623.
      View in: PubMed
    47. Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44. PMID: 20683399.
      View in: PubMed
    48. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8. PMID: 20660382.
      View in: PubMed
    49. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. PMID: 20558311.
      View in: PubMed
    50. Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA. Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol. 2010 May; 194(5):W401-6. PMID: 20410385.
      View in: PubMed
    51. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):667-74. PMID: 20171802.
      View in: PubMed
    52. Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys. 2010 Feb 04; 11(1):3073. PMID: 20160693.
      View in: PubMed
    53. Núñez R, Erwin WD, Wendt RE, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA. Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner. Mol Imaging Biol. 2010 Apr; 12(2):110-38. PMID: 20049543.
      View in: PubMed
    54. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92. PMID: 19685531.
      View in: PubMed
    55. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9. PMID: 19602564.
      View in: PubMed
    56. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw. 2009 Jun; 7 Suppl 2:S1-26. PMID: 19555588.
      View in: PubMed
    57. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11. PMID: 19451443.
      View in: PubMed
    58. Schechter NR, Erwin WD, Yang DJ, Kim EE, Munden RF, Forster K, Taing LC, Cox JD, Macapinlac HA, Podoloff DA. Radiation dosimetry and biodistribution of (99m)Tc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2009 Oct; 36(10):1583-91. PMID: 19396440.
      View in: PubMed
    59. Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imaging. 2009 Apr; 53(2):201-9. PMID: 19293768.
      View in: PubMed
    60. Rohren EM, Macapinlac HA. PET Imaging of Prostate Cancer: Other Tracers. PET Clin. 2009 Apr; 4(2):185-92. PMID: 27157010.
      View in: PubMed
    61. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15. PMID: 19332725.
      View in: PubMed
    62. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL, Harrell RK, Marom EM. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009 Mar; 50(3):340-7. PMID: 19258257.
      View in: PubMed
    63. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009 Feb; 50(2):231-8. PMID: 19164229.
      View in: PubMed
    64. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Inoue T, Macapinlac HA. Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. Eur J Nucl Med Mol Imaging. 2009 Jun; 36(6):894-902. PMID: 19156410.
      View in: PubMed
    65. Vikram R, Yeung HD, Macapinlac HA, Iyer RB. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol. 2008 Nov; 191(5):1545-51. PMID: 18941099.
      View in: PubMed
    66. Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):890-9. PMID: 18514781.
      View in: PubMed
    67. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008 Sep; 142(5):786-92. PMID: 18564354.
      View in: PubMed
    68. Schwartz DL, Macapinlac HA, Weber RS. FDG-PET staging of head and neck cancer--can improved imaging lead to improved treatment? J Natl Cancer Inst. 2008 May 21; 100(10):688-9. PMID: 18477798.
      View in: PubMed
    69. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr; 247(1):189-96. PMID: 18372468.
      View in: PubMed
    70. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med. 2008 Feb; 22(2):111-4. PMID: 18311535.
      View in: PubMed
    71. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med. 2008 Mar; 38(2):137-40. PMID: 18243849.
      View in: PubMed
    72. Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin RE. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant. 2008 Apr; 14(4):478-80. PMID: 18342791.
      View in: PubMed
    73. Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008 Feb; 46(1):23-9. PMID: 18297544.
      View in: PubMed
    74. Reed VK, Cavalcanti JL, Strom EA, Perkins GH, Oh JL, Tereffe W, Yu TK, Yeung H, Whitman GJ, Bedrosian I, Macapinlac HA, Buchholz TA, Woodward WA. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):435-40. PMID: 18164831.
      View in: PubMed
    75. Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging. 2007 Nov 26; 7:189-94. PMID: 18055293.
      View in: PubMed
    76. Macapinlac HA. Positron Emission Tomography of the Brain. PET Clin. 2007 Jan; 2(1):1-13. PMID: 27157702.
      View in: PubMed
    77. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer. 2007 Nov 15; 110(10):2155-68. PMID: 17896784.
      View in: PubMed
    78. Cavalcanti JL, Núñez RF, Yeung HW, Mehran RJ, Macapinlac HA. Incidental finding of prostate cancer and adenomatous colon polyp in a patient with lung cancer. Clin Nucl Med. 2007 Nov; 32(11):871-3. PMID: 18075426.
      View in: PubMed
    79. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA. Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes. 2007 Nov; 115(10):694-6. PMID: 18058606.
      View in: PubMed
    80. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007 Nov-Dec; 27(6):1635-52. PMID: 18025508.
      View in: PubMed
    81. Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, Macapinlac HA. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology. 2007 Dec; 245(3):692-702. PMID: 17911538.
      View in: PubMed
    82. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16. PMID: 17904303.
      View in: PubMed
    83. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008 Jun; 109(3):417-26. PMID: 17653852.
      View in: PubMed
    84. Podoloff DA, Macapinlac HA. PET and PET/CT in management of the lymphomas. Radiol Clin North Am. 2007 Jul; 45(4):689-96, vii. PMID: 17706533.
      View in: PubMed
    85. Núñez R, Yeung HW, Swanston NM, Macapinlac HA. [FDG uptake in gall bladder in the PET and PET/CT scan of three oncology patients]. Rev Esp Med Nucl. 2007 Jul-Aug; 26(4):234-6. PMID: 17662192.
      View in: PubMed
    86. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007 May 01; 25(13):1753-9. PMID: 17470865.
      View in: PubMed
    87. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007 May 01; 25(13):1760-4. PMID: 17470866.
      View in: PubMed
    88. Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol. 2007 Mar; 35(1):10-6; quiz 17-20. PMID: 17337652.
      View in: PubMed
    89. Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol. 2007 Jan-Feb; 36(1):21-9. PMID: 17198889.
      View in: PubMed
    90. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34. PMID: 17146785.
      View in: PubMed
    91. Namwongprom S, Núñez R, Kim EE, Macapinlac HA. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med. 2007 Jan; 32(1):35-8. PMID: 17179801.
      View in: PubMed
    92. Won KS, Gayed I, Kim EE, Macapinlac H. Juvenile fibroadenoma of the breast demonstrated on 111in-octreotide SPECT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2007 Mar; 34(3):440. PMID: 17119960.
      View in: PubMed
    93. Macapinlac HA. Positron emission tomography of the brain. Neuroimaging Clin N Am. 2006 Nov; 16(4):591-603, viii. PMID: 17148021.
      View in: PubMed
    94. Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer. 2006 Oct 15; 107(8):1898-908. PMID: 16986125.
      View in: PubMed
    95. Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys. 2006 Oct; 33(10):3931-8. PMID: 17089855.
      View in: PubMed
    96. Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol. 2006 Oct; 187(4):1116-23. PMID: 16985164.
      View in: PubMed
    97. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006 Aug; 47(8):1267-73. PMID: 16883004.
      View in: PubMed
    98. Marom EM, Munden RF, Truong MT, Gladish GW, Podoloff DA, Mawlawi O, Broemeling LD, Bruzzi JF, Macapinlac HA. Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. J Thorac Imaging. 2006 Aug; 21(3):205-12. PMID: 16915065.
      View in: PubMed
    99. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9. PMID: 16794124.
      View in: PubMed
    100. Podoloff DA, Macapinlac HA. PET and PET/CT in Management of the Lymphomas. PET Clin. 2006 Jul; 1(3):243-50. PMID: 27157363.
      View in: PubMed
    101. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86. PMID: 17409902.
      View in: PubMed
    102. Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging. 2006 May; 21(2):137-45. PMID: 16770230.
      View in: PubMed
    103. Mawlawi O, Pan T, Macapinlac HA. PET/CT imaging techniques, considerations, and artifacts. J Thorac Imaging. 2006 May; 21(2):99-110. PMID: 16770227.
      View in: PubMed
    104. Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, Kohlmyer S, Macapinlac HA, Podoloff DA. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol. 2006 May; 186(5):1458-67. PMID: 16632745.
      View in: PubMed
    105. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging. 2006 Mar; 50(1):61-7. PMID: 16557205.
      View in: PubMed
    106. Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, Podoloff DA, Chasen M. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol. 2006 Feb; 186(2):308-19. PMID: 16423932.
      View in: PubMed
    107. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol. 2005 Dec 14; 11(46):7284-9. PMID: 16437629.
      View in: PubMed
    108. Macapinlac HA. FDG-PET in the evaluation of cervical cancer. Gynecol Oncol. 2005 Dec; 99(3 Suppl 1):S171-2. PMID: 16419203.
      View in: PubMed
    109. Frank SJ, Chao KS, Schwartz DL, Weber RS, Apisarnthanarax S, Macapinlac HA. Technology insight: PET and PET/CT in head and neck tumor staging and radiation therapy planning. Nat Clin Pract Oncol. 2005 Oct; 2(10):526-33. PMID: 16205772.
      View in: PubMed
    110. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005 Sep; 46(9):1481-7. PMID: 16157531.
      View in: PubMed
    111. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1406-11. PMID: 16133379.
      View in: PubMed
    112. Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology. 2005 Jul; 236(1):271-5. PMID: 15987980.
      View in: PubMed
    113. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005 Jul; 7(4):293-9. PMID: 15946589.
      View in: PubMed
    114. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005 Jun; 129(6):1364-70. PMID: 15942579.
      View in: PubMed
    115. Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J. 2005 May; 28(5):284-95. PMID: 16086543.
      View in: PubMed
    116. Martínez-Román S, Ramirez PT, Oh J, Viciedo MG, MacApinlac HA. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol. 2005 Mar; 96(3):888-91. PMID: 15721446.
      View in: PubMed
    117. Truong MT, Erasmus JJ, Macapinlac HA, Marom EM, Mawlawi O, Gladish GW, Sabloff BS, Bruzzi JF, Munden RF. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr. 2005 Mar-Apr; 29(2):205-9. PMID: 15772538.
      View in: PubMed
    118. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1136-43. PMID: 15718309.
      View in: PubMed
    119. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics. 2005 Jan-Feb; 25(1):191-207. PMID: 15653595.
      View in: PubMed
    120. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004 Dec; 183(6):1619-28. PMID: 15547201.
      View in: PubMed
    121. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85. PMID: 15386332.
      View in: PubMed
    122. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60. PMID: 15464463.
      View in: PubMed
    123. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac H. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med. 2004 Oct; 45(10):1734-42. PMID: 15471842.
      View in: PubMed
    124. Truong MT, Erasmus JJ, Munden RF, Marom EM, Sabloff BS, Gladish GW, Podoloff DA, Macapinlac HA. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 2004 Oct; 183(4):1127-32. PMID: 15385319.
      View in: PubMed
    125. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004 Sep 01; 64(17):5913-9. PMID: 15342366.
      View in: PubMed
    126. Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004 Jul-Aug; 10(4):262-70. PMID: 15383207.
      View in: PubMed
    127. Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol. 2004 Jul-Aug; 6(4):200-7. PMID: 15262235.
      View in: PubMed
    128. Truong MT, Erasmus JJ, Macapinlac HA, Podoloff DA. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol. 2004 Jun; 182(6):1587-9. PMID: 15150014.
      View in: PubMed
    129. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004 Jan; 45(1):17-21. PMID: 14734662.
      View in: PubMed
    130. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1943-51. PMID: 14688710.
      View in: PubMed
    131. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003 Sep; 44(9):1407-12. PMID: 12960184.
      View in: PubMed
    132. Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol. 2003 Jan-Feb; 5(1):26-31. PMID: 14499159.
      View in: PubMed
    133. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Schoder H, Larson SM, Macapinlac HA, Squire OD, Humm JL. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002 Jul; 43(7):876-81. PMID: 12097456.
      View in: PubMed
    134. Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med. 2002 Jun; 46(2):122-30. PMID: 12114875.
      View in: PubMed
    135. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002 Jun; 59(6):913-8. PMID: 12031380.
      View in: PubMed
    136. Sánchez Salmón A, Núñez R, Yeung H, Healey J, Macapinlac H. [FGD PET in a patient with pseudofractures from osteomalacia]. Rev Esp Med Nucl. 2002 Feb; 21(1):34-5. PMID: 11821000.
      View in: PubMed
    137. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002 Jan; 62(1):51-60. PMID: 11830312.
      View in: PubMed
    138. Nuñez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002 Jan; 43(1):46-55. PMID: 11801702.
      View in: PubMed
    139. Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging. 2002 Jan; 29(1):61-6. PMID: 11807608.
      View in: PubMed
    140. Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med. 2001 Sep; 45(3):235-44. PMID: 11788816.
      View in: PubMed
    141. Turlakow A, Yeung HW, Pui J, Macapinlac H, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med. 2001 Apr 09; 161(7):1003-7. PMID: 11295964.
      View in: PubMed
    142. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med. 2001 Mar; 26(3):193-7. PMID: 11245108.
      View in: PubMed
    143. Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, Chisin R, Larson SM. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001 Feb; 28(2):155-64. PMID: 11303885.
      View in: PubMed
    144. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med. 2001 Jan; 42(1):77-8. PMID: 11197984.
      View in: PubMed
    145. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract. 2000 Nov-Dec; 6(6):460-4. PMID: 11155220.
      View in: PubMed
    146. Nuñez RF, Yeung HW, Macapinlac HA, Castro-Malaspina H, Larson SM. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med. 2000 Sep; 25(9):676-8. PMID: 10983752.
      View in: PubMed
    147. Chisin R, Macapinlac HA. The indications of FDG-PET in neck oncology. Radiol Clin North Am. 2000 Sep; 38(5):999-1012. PMID: 11054965.
      View in: PubMed
    148. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000 Jul; 27(7):861-6. PMID: 10952499.
      View in: PubMed
    149. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000 Mar; 85(3):1107-13. PMID: 10720047.
      View in: PubMed
    150. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000 Mar; 18(6):1173-80. PMID: 10715285.
      View in: PubMed
    151. Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid. 2000 Feb; 10(2):177-83. PMID: 10718556.
      View in: PubMed
    152. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan; 43(1):18-24. PMID: 10813118.
      View in: PubMed
    153. Macapinlac HA, Yeung HW, Larson SM. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging. 1999 Nov; 2(6):311-316. PMID: 14516613.
      View in: PubMed
    154. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging. 1999 Oct; 2(5):255-260. PMID: 14516649.
      View in: PubMed
    155. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999 Oct; 178(4):282-7. PMID: 10587184.
      View in: PubMed
    156. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999 Jul; 84(7):2291-302. PMID: 10404792.
      View in: PubMed
    157. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 1999 May; 2(3):159-171. PMID: 14516540.
      View in: PubMed
    158. Macapinlac HA, Humm JL, Akhurst T, Osman I, Pentlow K, Shangde C, Yeung HW, Squire O, Finn RD, Scher HI, Larson SM. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. Clin Positron Imaging. 1999 May; 2(3):173-181. PMID: 14516541.
      View in: PubMed
    159. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med. 1999 Apr; 24(4):281-2. PMID: 10466532.
      View in: PubMed
    160. Erdi YE, Macapinlac H, Larson SM, Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging. 1999 Jan; 2(1):41-46. PMID: 14516552.
      View in: PubMed
    161. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract. 1998 Sep-Oct; 4(5):282-6. PMID: 15251726.
      View in: PubMed
    162. Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1177-83. PMID: 9719130.
      View in: PubMed
    163. Akhurst T, Boland P, Macapinlac H, Finn R, Yeung HW, Squire O, Larson SM. Excess Muscle FDG Uptake in an Euglycaemic Patient That Is Corrected by Fasting. Clin Positron Imaging. 1998 Mar; 1(2):131-133. PMID: 14516602.
      View in: PubMed
    164. Macapinlac HA, Larson SM. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am. 1997 Nov-Dec; 3(6):333-5. PMID: 9403044.
      View in: PubMed
    165. el-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med. 1997 Aug; 38(8):1208-10. PMID: 9255151.
      View in: PubMed
    166. Yeung H, Macapinlac H. First impressions. A 21-yr-old woman with adenocarcinoma of the pelvis. What is the radiopharmaceutical? What are the findings? J Nucl Med. 1996 Dec; 37(12):7A, 1994. PMID: 8999117.
      View in: PubMed
    167. Yeung HW, Imbriaco M, Zhang JJ, Macapinlac H, Goldsmith SJ, Larson SM. Visualization of myocardial metastasis of carcinoid tumor by indium-111-pentetreotide. J Nucl Med. 1996 Sep; 37(9):1528-30. PMID: 8790210.
      View in: PubMed
    168. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn R, Kemeny N, Larson SM. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med. 1996 Apr; 37(4 Suppl):29S-32S. PMID: 8676201.
      View in: PubMed
    169. Macapinlac HA, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, Larson SM. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med. 1996 Apr; 37(4 Suppl):25S-29S. PMID: 8676200.
      View in: PubMed
    170. Reinsel RA, Veselis RA, Feshchenko VA, Di Resta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg R, Macapinlac H, et al. Target detection and the prefrontal cortex. A PET scan study of the P300 event-related potential. Ann N Y Acad Sci. 1995 Dec 15; 769:393-7. PMID: 8595041.
      View in: PubMed
    171. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin-receptor imaging in lymphoma. Semin Nucl Med. 1995 Jul; 25(3):262-71. PMID: 7570045.
      View in: PubMed
    172. Abdel-Dayem H, Bag R, Macapinlac H, Elgazzar AH, Habbab N, Pescatore F, Kempf J. Diffuse Tl-201 uptake in the lungs. Etiologic classification and pattern recognition. Clin Nucl Med. 1995 Feb; 20(2):164-72. PMID: 7720309.
      View in: PubMed
    173. Scott AM, Macapinlac H, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SD, et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med. 1995 Jan; 36(1):100-3. PMID: 7799059.
      View in: PubMed
    174. Caluser C, Scott A, Macapinlac H, Yeh S, Rosenfelt N, Farid B, Abdel-Dayem HM, Larson SM, Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med. 1995 Jan; 20(1):75. PMID: 7895447.
      View in: PubMed
    175. Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med. 1994 Dec; 35(12):1976-84. PMID: 7989980.
      View in: PubMed
    176. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, Kalaigian H, Yeh SD, Larson SM. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med. 1994 Nov; 21(11):1198-205. PMID: 7859771.
      View in: PubMed
    177. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994 Nov; 35(11):1748-52. PMID: 7525900.
      View in: PubMed
    178. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med. 1994 Sep; 35(9):1407-17. PMID: 8071684.
      View in: PubMed
    179. Larson SM, Divgi C, Scott A, Daghighian F, Macapinlac H, Welt S. Current status of radioimmunodetection. Nucl Med Biol. 1994 Jul; 21(5):721-9. PMID: 9241648.
      View in: PubMed
    180. Scott AM, Macapinlac H, Zhang JJ, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. Nucl Med Biol. 1994 Jul; 21(5):775-84. PMID: 9241654.
      View in: PubMed
    181. Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol. 1994 Jul; 21(5):731-8. PMID: 9241649.
      View in: PubMed
    182. Abdel-Dayem HM, Scott A, Macapinlac H, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med. 1994 Jan; 21(1):57-81. PMID: 8088287.
      View in: PubMed
    183. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med. 1993 Sep; 18(9):751-3. PMID: 8403716.
      View in: PubMed
    184. Rusch V, Macapinlac H, Heelan R, Kramer E, Larson S, McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning. A helpful new adjunct to computed tomography in evaluating non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993 Aug; 106(2):200-4. PMID: 8393504.
      View in: PubMed
    185. Daghighian F, Pentlow KS, Larson SM, Graham MC, DiResta GR, Yeh SD, Macapinlac H, Finn RD, Arbit E, Cheung NK. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993 May; 20(5):402-9. PMID: 8519259.
      View in: PubMed
    186. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol. 1993; 32(7-8):709-15. PMID: 8305216.
      View in: PubMed
    187. Caluser C, Healey J, Macapinlac H, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Tl-201 uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone imaging. Clin Nucl Med. 1992 Sep; 17(9):751-3. PMID: 1395357.
      View in: PubMed
    188. Roistacher N, Preminger M, Macapinlac H, Pierri MK. Myocardial entrapment by lymphoma: a cause of reversible segmental left ventricular dysfunction. Am Heart J. 1992 Aug; 124(2):516-21. PMID: 1636600.
      View in: PubMed
    189. Caluser C, Macapinlac H, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med. 1992 Jul; 17(7):565-72. PMID: 1638838.
      View in: PubMed
    190. Hoener B, Engelstad BL, Ramos EC, Macapinlac HA, Price DC, Johnson TR, White DL. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging. 1991 May-Jun; 1(3):357-62. PMID: 1802149.
      View in: PubMed
    191. Accuracy of FDG-PET in gastric cancer. Clinical Positron Imaging (Netherlands). 1:213-221.
    192. Differential metabolism and pharmacokinetics of L-[1-11C]-methionine and 2-[18F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer. Clinical Positron Imaging (Netherlands). 2:173-181.
    193. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology. 21:33-39.
    194. PET Imaging of Prostate Cancer. PET Clinics. 4:185-192.
    195. The role of 18F-FDG PET/CT in diagnosis and staging of musculoskeletal soft tissue sarcomas. Clinical and Translational Imaging. 3:111-121.
    196. Diffuse large B-Cell lymphoma. Radiology. 280:220-229.
    197. Reply. Journal of Nuclear Medicine. 57:991.
    198. Assessing response to therapy. 25-33.
    199. FDG-PET in esophageal cancer. Clinical Positron Imaging (Netherlands). 2:255-260.
    200. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clinical Positron Imaging (Netherlands). 2:159-171.
    201. Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clinical Positron Imaging (Netherlands). 3:107-114.
    202. Factors affecting quantification in PET/CT imaging. Current Medical Imaging Reviews. 4:34-45.
    203. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clinical Positron Imaging (Netherlands). 2:41-46.
    204. Positron Emission Tomography of the Brain. PET Clinics. 2:1-13.
    205. Qualitative and quantitative comparison of gated blood pool single photon emission computed tomography using low-energy high-resolution and SMARTZOOM collimation. Nuclear Medicine Communications. 38:35-43.
    206. Tracer imaging in lung cancer. European Journal Of Nuclear Medicine. 22:1355.
    207. Carcinoid tumor of the kidney. Urologic Oncology. 5:108-111.
    208. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. International Braz J Urol. 34:778.
    209. Defining the role of FDG PET in head and neck cancer. Clinical Positron Imaging (Netherlands). 2:311-316.
    210. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging. 1-10.
    211. Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. Journal of Applied Clinical Medical Physics. 11:217-228.
    212. Skeletal tumor burden on baseline 18F-fluoride PET/CT predicts bone marrow failure after 223Ra therapy. Clinical Nuclear Medicine. 41:268-273.
    213. Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies. European Journal of Nuclear Medicine and Molecular Imaging. 1-11.
    214. Colorectal carcinoma. 108-123.
    215. Excess muscle FDG uptake in an euglycaemic patient that is corrected by fasting. Clinical Positron Imaging (Netherlands). 1:131-133.
    216. PET and PET/CT in Management of the Lymphomas. PET Clinics. 1:243-250.
    217. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. European Journal of Cancer.
    218. Erratum. European Journal Of Nuclear Medicine. 22:1355.
    MACAPINLAC's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description